Our study findings support the inclusion of TMG (POT1, TERF2IP, ACD, and TERT) on genetic testing panels when a familial melanoma case exhibits spitzoid morphology in at least 25% of the tumor cells. The gene discussed is TERF2IP; the disease is neoplasm.